{"id":66706,"date":"2026-05-29T14:55:13","date_gmt":"2026-05-29T06:55:13","guid":{"rendered":"https:\/\/flcube.com\/?p=66706"},"modified":"2026-05-29T14:55:14","modified_gmt":"2026-05-29T06:55:14","slug":"henlius-biotech-initiates-china-dosing-in-phase-ii-iii-trial-of-novel-pd-l1-adc-hlx43-for-squamous-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66706","title":{"rendered":"Henlius Biotech Initiates China Dosing in Phase II\/III Trial of Novel PD-L1 ADC HLX43 for Squamous NSCLC"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shanghai Henlius Biotech Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2696:HKG\">HKG: 2696<\/a>) announced the <strong>first patient dosing in China<\/strong> for an <strong>international multicenter Phase II\/III clinical study<\/strong> evaluating <strong>HLX43<\/strong> as monotherapy or in combination with <strong>pimurutamab (HLX07)<\/strong> versus <strong>docetaxel<\/strong> for <strong>advanced\/metastatic squamous non-small cell lung cancer (NSCLC)<\/strong> in patients who have failed prior therapy.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-design-amp-patient-population\" class=\"wp-block-heading\">Clinical Trial Design &amp; Patient Population<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Phase<\/strong><\/td><td>Phase II\/III<\/td><\/tr><tr><td><strong>Design<\/strong><\/td><td>International multicenter<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Advanced\/metastatic squamous NSCLC post-prior therapy failure<\/td><\/tr><tr><td><strong>Treatment Arms<\/strong><\/td><td>HLX43 monotherapy<br>HLX43 + HLX07 combination<br>Docetaxel (control)<\/td><\/tr><tr><td><strong>Geographic Scope<\/strong><\/td><td>Global study with China enrollment initiated<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profiles-amp-mechanisms-of-action\" class=\"wp-block-heading\">Drug Profiles &amp; Mechanisms of Action<\/h2>\n\n\n\n<h3 id=\"h-hlx43-novel-pd-l1-antibody-drug-conjugate-adc\" class=\"wp-block-heading\">HLX43 \u2013 Novel PD-L1 Antibody-Drug Conjugate (ADC)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> PD-L1<\/li>\n\n\n\n<li><strong>Payload:<\/strong> Novel DNA topoisomerase I inhibitor small molecule toxin<\/li>\n\n\n\n<li><strong>Linker Technology:<\/strong> Peptide linker (licensed technology)<\/li>\n\n\n\n<li><strong>Antibody Platform:<\/strong> Henlius&#8217; proprietary PD-L1 antibody<\/li>\n\n\n\n<li><strong>Indication Focus:<\/strong> Advanced\/metastatic solid tumors<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Combines immune checkpoint targeting with cytotoxic payload delivery<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-hlx07-pimurutamab-egfr-targeting-monoclonal-antibody\" class=\"wp-block-heading\">HLX07 (Pimurutamab) \u2013 EGFR-Targeting Monoclonal Antibody<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> EGFR (epidermal growth factor receptor)<\/li>\n\n\n\n<li><strong>Development Status:<\/strong> Independently developed by Henlius<\/li>\n\n\n\n<li><strong>Previous Data:<\/strong> Phase Ib\/II results (February 2023) showed favorable safety and tolerability in combination with chemotherapy for advanced solid tumors<\/li>\n\n\n\n<li><strong>Current Development:<\/strong> Multiple ongoing studies in China<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-current-hlx07-clinical-pipeline\" class=\"wp-block-heading\">Current HLX07 Clinical Pipeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study<\/th><th>Indication<\/th><th>Phase<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Monotherapy Trial<\/strong><\/td><td>Advanced cutaneous squamous cell carcinoma (CSCC) and other solid tumors<\/td><td>Phase II<\/td><td>Ongoing in China<\/td><\/tr><tr><td><strong>Combination Trial<\/strong><\/td><td>HLX07 + Hansizhuang (serplulimab) + chemotherapy for advanced squamous NSCLC<\/td><td>Phase II\/III<\/td><td>International multicenter, ongoing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-significance-amp-market-context\" class=\"wp-block-heading\">Strategic Significance &amp; Market Context<\/h2>\n\n\n\n<h3 id=\"h-therapeutic-innovation\" class=\"wp-block-heading\">Therapeutic Innovation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual Targeting Approach:<\/strong> Combines PD-L1 ADC (HLX43) with EGFR inhibitor (HLX07) to address multiple resistance mechanisms<\/li>\n\n\n\n<li><strong>ADC Differentiation:<\/strong> HLX43 represents a novel approach to PD-L1 targeting by delivering cytotoxic payload directly to PD-L1 expressing tumor cells<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Squamous NSCLC patients who fail prior therapy have limited effective treatment options<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-competitive-landscape-for-squamous-nsclc\" class=\"wp-block-heading\">Competitive Landscape for Squamous NSCLC<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Therapeutic Approach<\/th><th>Key Players<\/th><th>Current Status<\/th><th>Henlius Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>PD-1\/PD-L1 Monotherapy<\/strong><\/td><td>Merck, BMS, AstraZeneca<\/td><td>Standard of care<\/td><td>ADC approach may overcome resistance<\/td><\/tr><tr><td><strong>Chemotherapy<\/strong><\/td><td>Various generics<\/td><td>Docetaxel control arm<\/td><td>Targeted therapy with potentially better safety<\/td><\/tr><tr><td><strong>EGFR Inhibitors<\/strong><\/td><td>Lilly, Merck KGaA<\/td><td>Limited efficacy in squamous NSCLC<\/td><td>Combination strategy addresses heterogeneity<\/td><\/tr><tr><td><strong>Novel ADCs<\/strong><\/td><td>Daiichi Sankyo, AbbVie<\/td><td>Emerging class<\/td><td>First PD-L1 ADC in late-stage development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-development-strategy-amp-commercial-implications\" class=\"wp-block-heading\">Development Strategy &amp; Commercial Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Ambition:<\/strong> International multicenter trial design indicates global commercial aspirations<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Success would validate both Henlius&#8217; ADC platform and EGFR antibody capabilities<\/li>\n\n\n\n<li><strong>China Leadership:<\/strong> Positions Henlius as innovator in next-generation immuno-oncology combinations<\/li>\n\n\n\n<li><strong>Pipeline Synergy:<\/strong> Leverages existing serplulimab (Hansizhuang) infrastructure and expertise<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential for HLX43 and HLX07. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market access challenges in the highly competitive NSCLC landscape.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/600276_20260529_Z0O7.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600276_20260529_Z0O7.\"><\/object><a id=\"wp-block-file--media-6341dfd6-2bb8-4752-a668-933309adaabc\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/600276_20260529_Z0O7.pdf\">600276_20260529_Z0O7<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/600276_20260529_Z0O7.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6341dfd6-2bb8-4752-a668-933309adaabc\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing in China for an&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,29,270,862],"class_list":["post-66706","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-combination-therapy","tag-henlius-biotech","tag-hkg-2696"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Henlius Biotech Initiates China Dosing in Phase II\/III Trial of Novel PD-L1 ADC HLX43 for Squamous NSCLC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing in China for an international multicenter Phase II\/III clinical study evaluating HLX43 as monotherapy or in combination with pimurutamab (HLX07) versus docetaxel for advanced\/metastatic squamous non-small cell lung cancer (NSCLC) in patients who have failed prior therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66706\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Henlius Biotech Initiates China Dosing in Phase II\/III Trial of Novel PD-L1 ADC HLX43 for Squamous NSCLC\" \/>\n<meta property=\"og:description\" content=\"Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing in China for an international multicenter Phase II\/III clinical study evaluating HLX43 as monotherapy or in combination with pimurutamab (HLX07) versus docetaxel for advanced\/metastatic squamous non-small cell lung cancer (NSCLC) in patients who have failed prior therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66706\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-29T06:55:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-29T06:55:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66706#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66706\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Henlius Biotech Initiates China Dosing in Phase II\\\/III Trial of Novel PD-L1 ADC HLX43 for Squamous NSCLC\",\"datePublished\":\"2026-05-29T06:55:13+00:00\",\"dateModified\":\"2026-05-29T06:55:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66706\"},\"wordCount\":463,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Combination therapy\",\"Henlius Biotech\",\"HKG: 2696\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66706#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66706\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66706\",\"name\":\"Henlius Biotech Initiates China Dosing in Phase II\\\/III Trial of Novel PD-L1 ADC HLX43 for Squamous NSCLC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-29T06:55:13+00:00\",\"dateModified\":\"2026-05-29T06:55:14+00:00\",\"description\":\"Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing in China for an international multicenter Phase II\\\/III clinical study evaluating HLX43 as monotherapy or in combination with pimurutamab (HLX07) versus docetaxel for advanced\\\/metastatic squamous non-small cell lung cancer (NSCLC) in patients who have failed prior therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66706#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66706\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66706#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Henlius Biotech Initiates China Dosing in Phase II\\\/III Trial of Novel PD-L1 ADC HLX43 for Squamous NSCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Henlius Biotech Initiates China Dosing in Phase II\/III Trial of Novel PD-L1 ADC HLX43 for Squamous NSCLC - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing in China for an international multicenter Phase II\/III clinical study evaluating HLX43 as monotherapy or in combination with pimurutamab (HLX07) versus docetaxel for advanced\/metastatic squamous non-small cell lung cancer (NSCLC) in patients who have failed prior therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66706","og_locale":"en_US","og_type":"article","og_title":"Henlius Biotech Initiates China Dosing in Phase II\/III Trial of Novel PD-L1 ADC HLX43 for Squamous NSCLC","og_description":"Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing in China for an international multicenter Phase II\/III clinical study evaluating HLX43 as monotherapy or in combination with pimurutamab (HLX07) versus docetaxel for advanced\/metastatic squamous non-small cell lung cancer (NSCLC) in patients who have failed prior therapy.","og_url":"https:\/\/flcube.com\/?p=66706","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-29T06:55:13+00:00","article_modified_time":"2026-05-29T06:55:14+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66706#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66706"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Henlius Biotech Initiates China Dosing in Phase II\/III Trial of Novel PD-L1 ADC HLX43 for Squamous NSCLC","datePublished":"2026-05-29T06:55:13+00:00","dateModified":"2026-05-29T06:55:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66706"},"wordCount":463,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial approval \/ initiation","Combination therapy","Henlius Biotech","HKG: 2696"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66706#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66706","url":"https:\/\/flcube.com\/?p=66706","name":"Henlius Biotech Initiates China Dosing in Phase II\/III Trial of Novel PD-L1 ADC HLX43 for Squamous NSCLC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-29T06:55:13+00:00","dateModified":"2026-05-29T06:55:14+00:00","description":"Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing in China for an international multicenter Phase II\/III clinical study evaluating HLX43 as monotherapy or in combination with pimurutamab (HLX07) versus docetaxel for advanced\/metastatic squamous non-small cell lung cancer (NSCLC) in patients who have failed prior therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66706#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66706"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66706#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Henlius Biotech Initiates China Dosing in Phase II\/III Trial of Novel PD-L1 ADC HLX43 for Squamous NSCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66706","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66706"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66706\/revisions"}],"predecessor-version":[{"id":66709,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66706\/revisions\/66709"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66706"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66706"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66706"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}